Alamar Biosciences (NASDAQ:ALMR) Issues Earnings Results, Beats Expectations By $0.03 EPS

Alamar Biosciences (NASDAQ:ALMR) issued its quarterly earnings data on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03, FiscalAI reports. The company had revenue of $33.55 million for the quarter.

Alamar Biosciences Stock Performance

Alamar Biosciences stock traded down $1.14 during midday trading on Thursday, hitting $26.25. 143,655 shares of the company’s stock were exchanged, compared to its average volume of 428,914. Alamar Biosciences has a 52-week low of $18.84 and a 52-week high of $39.61. The stock’s 50-day moving average price is $30.38. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.23 and a current ratio of 11.85. The firm has a market capitalization of $1.82 billion and a P/E ratio of -13.39.

Alamar Biosciences News Roundup

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported Q3 revenue of $33.55 million, up 68% year over year, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. It also raised its 2026 revenue guidance to $121 million–$123 million, bolstering the growth outlook. Alamar Q3 revenue and guidance
• Positive Sentiment: Alamar will work with GSK on a large-scale study using its NULISA platform to examine protein signatures across multiple disease areas. The collaboration could increase the platform’s visibility, although no financial terms were disclosed. Alamar and GSK collaboration
• Positive Sentiment: Analysts raised price targets: TD Cowen moved its target to $36 and maintained a Buy rating, while BofA Securities raised its target to $35 from $31. Higher targets may reinforce confidence in the company’s prospects. TD Cowen rating information BofA Securities price target
• Neutral Sentiment: Alamar announced plans to participate in upcoming investor conferences. These events may provide opportunities to discuss its business and outlook, but no new financial information was included in the announcement. Investor conference announcement
• Negative Sentiment: Major shareholder Corporate GP VI Ltd. Qiming disclosed additional stock sales, including 43,930 shares on Nov. 2 and 143,706 shares on Oct. 30. The repeated selling and reduction in its holdings could pressure investor sentiment; the filings do not state the reason for the sales. Major shareholder sales

Insider Buying and Selling at Alamar Biosciences

In other Alamar Biosciences news, major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $29.84, for a total value of $1,310,871.20. Following the sale, the insider owned 160,913 shares of the company’s stock, valued at $4,801,643.92. This trade represents a 21.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 1,387,636 shares of company stock valued at $41,234,931.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ALMR. Braidwell LP purchased a new stake in Alamar Biosciences in the second quarter valued at approximately $29,365,000. Wellington Management Group LLP purchased a new position in Alamar Biosciences in the 2nd quarter worth approximately $12,407,000. State Street Corp purchased a new position in Alamar Biosciences in the 2nd quarter worth approximately $3,930,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Alamar Biosciences by 18.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock worth $2,280,000 after buying an additional 10,461 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Alamar Biosciences in the 2nd quarter worth $283,000.

Wall Street Analysts Forecast Growth

ALMR has been the topic of several analyst reports. TD Cowen upped their price target on Alamar Biosciences from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. raised their price objective on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Stifel Nicolaus boosted their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings lowered shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Alamar Biosciences currently has a consensus rating of “Hold” and a consensus target price of $33.00.

About Alamar Biosciences

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.